Учитывая высокий риска возникновения осложнений при расширенных хирургических вмешательствах в осложнения. Complications after gynecological cancer expanded operations.


Чтобы посмотреть этот PDF файл с форматированием и разметкой, скачайте файл и откройте на своем компьютере.
5.  \r . . (\r \r  "  \n#   \r \n  \n \n // 1\r \n \r \r  " ,    \r \r : ! . %! \n , 1982. . 96-100. 6. \n\n . . ( \n  \r \n" \n  \r   //  \n  \n !"\r / . 1# , 2012. 2. . 35-38. 7. +\r . ., ( . . ,"      \n \r# \r //    \n  . .,1998. . 3. 2. .100-110. 8. %  . ., ;\n\r . .  \r \r \r \r   \r \r \n \n  // $\r  \n : ! . ., 2003. . 216. 9. Fujicawa K., Miyamoto ., Ihara Y. et al. High incidence of severe urologi e complications following radiotherapy for cervical cancer in Japan ese women // Gynecol. Oncol. 2001. V. 80. No. 1. P. 21-23. 10. Kenter G., Heintz A. P. Surgical treatment of cerv ical carcinoma // Int. J. Gynecol. Cancer. 2002. V. 12. No 5. P. 429-434. 11. Landoni F., Maneo A., Colombo A. et al. Randomized study of radical surgery versus radiotherapy for stage Ib-lla cervical cancer // La ncet. 1997. V. 350. No. 9077. P. 535 - 540. )" :  . .,  .  \n ,   , \r \r %0 , "\r . \n  \r  \n  \r  %4 , . %! \n . \n\r . .,  .  \n ,   , "\r & \n \n    \n \r    , .   . )"\r \n\r      2 (7,6 %  \n    )   . 0   "\r # " 6  \r   \r " \r  " . , \n \n\r \r # \n \r \r"  .  \n   . \r \n \r \n \r  . (\n # \n  \r #  . \r  \r &# \r \n\n  . 7# \r  # "  " 32     \r\r#   . (  # #  \r 1,8 %  !#   !!   " 7 \n   \r  . 1\n !" ,   \r      #  & *'* : 1. 7# \n  \n \n , \n  \n , \r&   " !    \n \n "!\r  \n  \n\r   ,  \r \n  \n "\r     , \n ! #  \r (49,0 %) !# . 2. $!   \r &    \r #   , \r\n " ! \r !   (  40 %  !&   ! \r ),     \r \r#   ( ! 30 %) !"\r \n  ( ! 25 %). 3. /\r \r \n  \n \r"\n\r        \n \r# \r \n\n , ! &#  \n\n \n\n \n\n  -, \n     . )  + (%(1%* 1. 7 . . ) \n\r \r  \n\n . .:  , 1989. 2.  #\n\r \n . ., 0 . .,  !\r . .,  \n . .,  !\r . . .!   \r   "  \n /8,    \n II  // 1 \n  \n   . 1# , 2012. 4. .42. 3.  ., 8# . )\n#     \n  \n \n . .:  , 1960. 4. \r . ., " \n . ., #\n\r . . ( \n \n " !"\r  "  #"\r \n\r \n // /#"\r \n\r  \n#  \n . ., 2006. 6. .18-27. "\r \r  " , \r\r \n 3  7  .    \r \r \r  "   &     "\r& \r& , \n !  \n  \n\r  . - #   \r# # !# \r \r  " !   \r \n  \r \r    \n . (\n\n       # !"# \r\r    &# \r" # \n#    # ! [5,8]. 0  , \r \r \n    \n " ,  !"\r "! " .  !    \r\r 7 (26,9 %  \n    ) \n . 4 \n II  \r  \r# \r \r \r# \r ,  \n  \n \n " "!   \r  "   \n\n "\n   \n " . " #   !"   ! \r \r # , "!   \r  " \n\r  !# \n \r \r \n  .  , \r#    \n \n \r" .  \r    \r !   \r   "   \n \n [2].  !"\r ! \r\n \r ,      \r\r . #   \r\r " \r   \r\r  # # \n   , \r     \n \n  " \r [4]. $ \n" &  \r   #"\r # . (\r \r"\n\r \n   \r\r . (  " \n\n \n  \r   !   , \r"     \n \r # \n\n   #    ,      !5\n\r \r " \n\n \r  ! \n  \r , "\n  "\r , !   \r \r"  \r  !  72     \r \r \r# \r . 0   !  # # 3 (11,5 %  \n    )   . (    # ,   \n \n  #"\r # \n   \n\n " '  , \r  # ,  # !\n , \n\r  "  !5'   "# \r  & \r  #"\r \r \n , \n"\r&   & \r  \n 61 . 1\n  ,  \n\n    \r  #  \n\n \n  #"\r \r   " &   [6].     \r#   \r 8 !# ,   \r 30,7 %  !& \n \r \r\r   .  \n \n     \r " \r &  . 0      \n \n \r# \r \r"\n  \r  " (10 %) "\r \r & \n \r   (3050 %) [9]. \r" \n \r  , \r\n& \r \n\r  \r ! \n \r"  \r  \r  "   \r  "   \n \n , & \r   \n  \n\r \r  " , \n    \n    \r  \r   "\r \r\r [5]. 1\n ,  \n    , \n \r \r \n\r       8 % (Rolf ., Bang . etal., 2006). 2 \n \r Tsursaki ., Hoshino . (2004)   "     \r  68,1 % & , \r  \n#  \n ,  59,1 %      "\r \n\n  \r #  ( \n\r  ,   ), \n !"  . 3- !#   \r  \r "  # \r"  !\r    .  \r    !\n#  !  ,  !# "\r "\n    \n  \r  \r \n  \n\r  " . +\n   \r # "\r \r \r& ,     \r 5,3 % (3 \n )  !& \n \r \r !# , 11,5 %  \n    . ( \r  \r \r   #   #  \r \n \r  " ,  !  \r \n &  \n \r  \n \r  " . (\r \r  " \r" \n    \r  "   \n \n , \n   \n , #\r  "\r    \n \r  "' . !    \n , !"\n \r  " ,  ! \r \r  " \r"\n \n\r "  \r \n  \r .  \r  "  \r  !  , "  \r  " \n  \n \r ( \n , ! \r ,  " "    \r\r \n #  ). 0#    "  \r     ,    "# \n"\r ,   !# !  \n . (\r \r  " \r" \n      \r , \n# \r"\n !" \r# !" \r  " ,  !   \r&   \n \n !" \r" # \n \r "\n \r  " \r  " \n . 0 \r \r \r  "  ,    \n    . \n   \r \r  .      "   \n\r (1 %), !   (2 %)  \n  # (1 %). +\n        \r  !"\r \n\r \r&  " \r& \r& (12 %),  -  \r  " \n\r (10 %) "\r \r & \n (3050 %) !"\r  "!  \n \n  (510 %) [9,10,11]. + +'#  . (\r  \n\n  "   , \r"\n&       \n \r# \r !#  "\n \r \r!"\r  \n \r  . 5(% +* .('*    \r     53 !#  "\n \r \r!"\r  \n \r  ,  \r  "  2009  2012 .  \n \n \n    , )  !\n \n   \n  .   , !  \n \n    . %\n , %! \n !  \n \n \n \n    , \n\n .   , . %\n , . %! \n . ,"  41 \n ! " \n  \n \n I IIa  , 12 !# " \n  \n II  .  !# \r \r \r# \r    \n II  . - \r"  !#  \r 46,4 5,1  . -  "   \r  ! \r # ! \r  #  \r , !&   . #  \n ,   ,     ! \r  \n\r " \n  !# , !  \n . ( !!\n     #"\r #  ( Biostat. \r$1+((* +'#  2 1/'#  . ," 53 \r !# " \r      \r\r 26 (49,0 %)   . $   &   , \r\n " ! \r !   , \n \n  "  ! \n  !   \n\n  " \r\r 9   ,   \r 34,6 %  \n    , "  2 (7,7 %),    1 \n (3,8 %). \r ,    \n \n  \r"\n    ,  "\r "\r   #\n    \r  \n ,         !# . .!   \n \r# \r \n"\r ! \n      \r"\r "\r \r   . (# #    \r#\r#  7  28    \n \r \r# \r       [7].    \r "!\r ,  \n         \n \n\n  . $ \r      \r"\n "     , \n !  "\r "    . %& \r  \r      \n   , \r"\r  #\n  \r \r#   ,  \r"   \r \r \r ' , \n   #"\r \r  "\n \n \r , !  \r  \r !   " . (   \n \r# \r    " \r\n  \n "\r \r #  \r   \n\r   [1]. (  " \r\r ,  \n  "     !#  "\n \r \r!"\r  \n \r        \n \r# \r ! \r \n \n \r\r&   ,   \n ,   " \r\r , \n!   46 %  77,5 % [10].  \r    \n  !# )* lb - II,   III (pTNM)  , \r        (    " \r\r \n#  \n ), \n , !"  \r , \r  !   \n\n [3]. ( \n \r   , \r"   \n \r# \r ,  \n  \n \n ( )* ) "# \r   \n"#  !#    \n \r    \n" [1,11].    \r  \r# \r \r \r# \r ,  \n  \n \n " "!   \r  "   \n\n "\n   \n " . " #   !"   ! \r \r # "!   \r  " \n\r  !# \n \r \r \n  ,  \n \r   \n   , \n\n \r # #  !   "!   \r " ( &  ), \n  \n \n  , ! & #  & \r" \r\r \r !#    \r  ,  \n"\r   "  [1,3,10]. (  \r      "\r#  " !# \r #  \n  " #  \n \n  , \r !   "!   \r \r" # \r  !   # "\r  , \r"\n\r " \n\r "  #  \r  " . $!       \r    \n \r   \r  " (1 %), \n\r (2 %), \n   \r (2 %) \r \n   \n\n (1 %), \n   \r  616.12-008.331-033.755  \n  \r\n\r  \n \n \n  \r\n  . ,  . ,  !" . , #$% . 1,4 , & .   \n \r \n \r \r \r \r \r \n\n\r  \n .  \r ,  \n    \r (010000,  \r ,  .   \r\n  \r , 3) [email protected]  !  \r \r  \n \n \n \r . " \r ,  \n    \r (160000, " \r ,  # \r ) [email protected] .   \n \r \n \n \r\n \n \r .  \r ,  \n    \r (010000,  \r ,  . $ \r ,2) [email protected] #% &! ' (\n\r (  \r\r ( \n\n\r ( \n( )\n\r  \n\n( \n\n , . ' (\n\r (454092, \n( , ' (\n\r (  * , . ' (\n\r ,  . &  , 64) [email protected]   \n \r    .  \r ,  \n    \r (010000,  \r ,  . #\n+\n \n , 51) [email protected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r \r :    \n \r  ,    \n ,     . COMPLICATIONS AFTER GYNECOLOGICAL CANCER EXPANDED O PERATIONS Vaskovskaya O. V. , Asabaeva R. I. , Digay L. K. , Shanazarov N. A. 1,4 , Kokoshko A. I. JSC "National Research Center for emergency care", Astana, Kazakhstan (010000, Astana, and ul.KereyZha nibek Khans 3) [email protected] RSE "Regional Cancer Center" in Shymkent, Kazakhsta n (160000, Shymkent, Baitursynova) [email protected] JSC "National Diagnostic Centre", Astana, Kazakhsta n (010000, Astana, st. Syganak 2) [email protected] GBOU VPO Chelyabinsk State Medical Academy, Ministr y of Russia, Chelyabinsk (454092, Russia, Chelyabin sk Region, Chelyabinsk, Vorovskiy st., 64) [email protected] JSC "Medical University of Astana" Astana, Republic of Kazakhstan (010000, Astana, st. Beibitshilik, 5 1) [email protected] A retrospective analysis of hospital record 53 pati ents with malignant tumors of female genitalia who received treatment between 2009 and 2012 in hospitals, Astan a, Shymkent, Chelyabinsk. Based on these data demonstrated that patients with cervical cancer, ut erine cancer are at high risk of postoperative comp lications were observed in almost half (49.0 %) patients. The most common complications were complications that led to infection of the abdominal cavity (40 % of the tota l number of side effects), complications of the uri nary organs (30%) and education limfokist (over 25 %). Given th e high risk of complications of advanced surgical procedures in oncogynecology, careful of their prev ention and correction as in the pre-and early posto perative period. Keywords:gynecological tumors, extended hysterectom y, postoperative complications. (1+#( )%+.* .  \r !   \n  ,   !"! , \r "\r     \r  , \r" \r \n \r !  \n .       #   \n   , \n \r"\n     \r 

Приложенные файлы

  • pdf 3310562
    Размер файла: 136 kB Загрузок: 0

Добавить комментарий